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Abstract 
 
S-glutathionylation occurs when reactive oxygen or nitrogen species react with 
protein cysteine thiols. Glutaredoxin-1 (Glrx) is a cytosolic enzyme which 
enzymatically catalyzes the reduction of S-glutathionylation, conferring reversible 
signaling function to proteins with redox-sensitive thiols. Glrx can regulate 
vascular hypertrophy and inflammation by regulating activity of NF-κB and actin 
polymerization.  VEGF-induced endothelial cell (EC) migration is inhibited by Glrx 
overexpression. In mice overexpressing Glrx, blood flow recovery, exercise 
function and capillary density were significantly attenuated after hind limb 
ischemia (HLI). Wnt5a and sFlt-1 were enhanced in the ischemic limb muscle 
and plasma respectively from Glrx TG mice. A Wnt5a-sFlt-1 pathway had been 
described in myeloid cells controlling retinal blood vessel development.  
Interestingly, a Wnt5a-sFlt-1 pathway was found also to play a role in EC to 
inhibit network formation. S-glutathionylation of NF-κB components inhibits its 
activation. Up-regulated Glrx stimulated Wnt5a-sFlt-1 pathway through 
enhancing NF-κB signaling. These studies show a novel role for Glrx in post-
ischemic neovascularization, which could define a potential target for therapy of 
impaired angiogenesis in the pathological conditions including diabetes. 
 
Introduction 
Imbalance in redox homeostasis is a hallmark of cardiovascular disease, 
particularly associated with diabetes. Enhanced levels of reactive oxygen and 
nitrogen species (RONS) act as deteriorating factors under pathophysiological 
settings [1–3], but are now also recognized as important redox signaling 
molecules[4,5]. The central way that RONS regulate intracellular signaling is by 
modulating redox-sensitive cysteine residues. The unique property of the 
cysteine thiol allows diverse reversible and irreversible oxidative post-
translational modifications (Ox-PTM) (Figure 1), resulting in regulatory 
mechanisms of cellular signaling. With the greater appreciation of redox signaling 
occurring during physiological and pathological conditions it is becoming 
apparent that we need to further understand Ox-PTMs [6]. Cardiovascular 
research has been leading the way to understand the intricate control of redox 
signaling [7,8]. 
 
Cysteine - the redox switch  
A pivotal site for Ox-PTMs resides at a terminal thiol (-SH) on the side chain of 
cysteine residues. The thiol gives rise to the thiolate anion (R-S-) to generate 
different oxidative states in reaction with RONS. Some of the modified states 
such as S-nitrosylation and sulfenylation are generally unstable and can be 
further modified to other Ox-PTMs including S-glutathionylation [9]. Some 
modifications are reversible; S-glutathionylation is reduced by Glrx, and protein 
disulfide is usually reversed by thioredoxin (Trx). On the other hand, higher level 
of oxidants can modify further the intermediates to sulfinic and sulfonic acid 
which are irreversible and detrimental to protein function, thus under these 
settings high oxidative conditions may accelerate disease progression [10]. Taken 
together the redox sensitive cysteines provide the intracellular mechanistic switch 
to sense fluctuations of redox levels controlling protein activity [11]. Moreover, this 
provides the intriguing potential that Ox-PTMs such as S-glutathionylation may 
actually protect proteins from irreversible oxidation [9,12]. 
Predicting which cysteine residues are redox sensitive is complex [13], the 
reactivity of the cysteine depends on the redox-milieu local to the cysteine, the 
reactivity of individual cysteine itself and the neighboring amino acid residues [14]. 
Databases have been compiled in different cardiovascular tissues to identify 
which cysteine residues act as a redox switch [10]. Additional studies along similar 
lines will be required to fully map and appreciate the redox potential of cysteines. 
 
Assessment of S-glutathionylation 
The “biotin switch assay” described previously provided a method to stably label 
the oxidation state to identify reversible modifications, S-Glutathionylation, S-
nitrosylation and sulfenic acid [15]. Initially, all free thiols undergo alkylation using 
an alkylating agent e.g. maleimide in the presence of SDS and assisted by 
heating. This is a critical step for stabilizing the oxidation state and therefore it is 
best conducted during lysing. Next, any free alkylation agent is removed by a 
desalting column. The reversible Ox-PTM can be selectively reduced permitting 
the free thiol to be labelled with a biotin-conjugated alkylating agent such as 
biotin-HPDP. After termination of the reaction by desalting, biotinylated proteins 
are purified with streptavidin-agarose beads. Subsequently, the proteins labelled 
by biotin-HPDP are eluted and can be detected by Western blotting and avidin-
based detection protocols [16]. The choice of reducing agent permits the 
identification of different modifications. For example ascorbate selectively 
reduces S-nitrosylation, sodium arsenite is used to detect sulfenic acid and 
recombinant-Glrx to identify S-glutathionylation. 
 
Glutaredoxin 
Glutaredoxins are small (12kd) enzymes belonging to the thioredoxin superfamily 
of oxidoreductases also known as thioltransferases [17]. Glrx works in conjunction 
with GSH as the co-substrate to specifically reduce protein-SSG mixed disulfides 
catalyzing de-glutathionylation. Glrx contain a conserved active site motif, Cys-X-
X-Cys [18]. It is the pKa of the N-terminal cysteine in the active site that is of 
critical importance for Glrx ability to catalyze the thiol-disulfide exchange. This 
cysteine has a lower pKa than free cysteine, thus reverses S-glutathionylation via 
a monothiol mechanism first forming a covalent enzyme intermediate Glrx-SSG 
which results in release of the reduced protein-SH [18]. Subsequently the Glrx-
SSG intermediate undergoes reduction by GSH to produce glutathione disulfide 
(GSSG) as the secondary product (Figure 2). There are two forms of Glrx in 
mammals, Glrx-1 and Glrx-2. Glrx-1 is mainly localized in the cytosol, however 
some reports suggest it may also reside in the nucleus[19]. Glrx-2 is 
predominantly localized to the mitochondria and also in the nucleus. Human 
Glrx2 exhibits only 34–36% identity with Glrx-1 and exerts less than 10% of the 
activity of Glrx-1 [20]. 
S-glutathionylation affects crucial pathways including cytoskeletal dynamics, 
protein folding, calcium handling (SERCA) and transcription factors (NF-κB), 
resulting in structural and functional changes[17]. Key proteins in important 
signaling pathways like phophatases are also affected by S-glutathionylation [21]. 
Most PTMs are known to induce either activation or inactivation of proteins, in 
contrast, S-glutathionylation can result in either functional inhibition such as 
eNOS and NF-κB[22–24] or activation, e.g. SERCA  [25,26], depending on the protein 
and reactive cysteine. Regulation and the role of endogenous Glrx in vivo are not 
well known. Glrx expression is increased in atherosclerotic human coronary 
artery [27], allergic mouse airway [28], and diabetic rat retina [29] and in type 2 
diabetic patients [30], suggesting that up-regulation of Glrx is associated with 
inflammation and oxidative stress. 
 
Glutathionylation in NF-κB pathway  
S-glutathionylation has the potential to negatively regulate the NF-κB pathway at 
multiple sites, and Glrx activates NF-κB by reversing the modification. The 
upstream inhibitory kappa kinase (IKK)- which phosphorylates IκB causing 
nuclear translocation of p65 (RelA) is known to be inhibited by S-
glutathionylation. In alveolar macrophages IKKβ is glutathionylated at Cys179 by 
H2O2 rendering IKKβ inactivation, 
[22] subsequently preventing IκBα degradation 
and NF-κB translocation. In pancreatic cancer cells hypoxia induced S-
glutathionylation of p65 inhibiting p65-DNA binding and transcription [31]. Another 
site of regulation lies at Cys62 of p50, similar to S-glutathionylation of p65 this 
prevents DNA binding of p50 [24]. Glrx reversal of S-glutathionylation provides a 
mechanistic switch to enhance transcription of NF-κB-dependent genes. Thus, 
Glrx overexpression prolongs NF-κB activation, while Glrx promoter contains two 
putative NF-κB binding sites and Glrx expression is positively regulated by NF-κB 
activation[32]. 
  
 
Wnt5a- sFlt-1 signaling 
The Wnt protein family is a large group of secreted cysteine-rich glycoproteins, 
named from the convergence of nomenclature of genes discovered in Drosophila 
(Wingless) and mammals (Int-1). Signaling by the Wnt family is highly conserved, 
regulating an extensive array of pathways from embryogenesis to tumorigenesis 
[33]. Canonical Wnt signaling involves the stabilization and nuclear translocation 
of β-catenin upon Wnt ligand binding to the seven-membrane domain receptor 
Frizzled complexed with Lrp5 [33]. β-catenin-independent signaling, termed non-
canonical signaling has been so far described with the following ligands Wnt4, 
Wnt5a and Wnt11. Non-canonical signaling is mediated via nuclear factor of 
activated T-cells (NFAT) or Wnt co-receptors Kny, Ror2 and Ryk [33].  
A set of studies from Stefatar et al reported that Wnt5a, a non-canonical ligand, 
plays a pivotal role in macrophage regulation of vascular branching during 
development [34]. In the deep layers of the retina an increase in post-natal 
angiogenesis was observed in mice lacking Wnt ligand transporter Wntless in 
myeloid cells. In the deep retinal layer myeloid and EC are in close contact at the 
sites of vessel branching and it was proven that this interaction allows myeloid 
cells to specifically control vessels density through Wnt5a regulation of sFlt-1 [34].  
The anti-angiogenic receptor sFlt-1 is the soluble isoform of Flt-1 also known as 
vascular endothelial growth factor receptor 1 (VEGFR1), and sFlt-1 sequesters 
vascular endothelial growth (VEGF) as it has a higher affinity than the pro-
angiogenic receptor, vascular endothelial growth factor receptor 2 (VEGFR2). 
Adenoviral sFlt-1 gene transfer inhibits ischemic limb revascularization [35]. Also, 
sFlt-1 is elevated after HLI in diabetic mice which showed impaired 
revascularization [36]. 
 
VEGF signaling and Flt 
VEGF is the major factor to stimulate arteriogenesis and angiogenesis. VEGF 
binds VEGFR2 (Kdr/Flk1) resulting in receptor dimerization and phosphorylation 
of tyrosine residues. VEGFR2 is the main transducer of VEGF endothelial cell 
proliferation, migration, and network formation. However, VEGF binds to 
VEGFR1 (Flt-1) with higher affinity than VEGFR2. Flt-1 gene encodes VEGFR1 
protein which contains an extracellular ligand-binding region, a transmembrane 
segment, and cytoplasmic tyrosine kinase domain. This full-length protein is 
referred to as the membrane-bound Flt-1 (mFlt). Alternative splicing in intron-13 
generates a short isoform which contains only shorter extracellular ligand-binding 
receptor. This short isoform, soluble protein (sFlt-1) still binds to VEGF but is 
without kinase activity. Flt-1 can function as a negative regulator for VEGFR2 
since a full-length membrane-tethered Flt-1 (mFlt) transduces a weaker signal 
than VEGFR2, and sFlt-1 can capture the VEGF ligand as a decoy to prevent its 
binding to VEGFR2 [37]. Elevated sFlt-1 causes pre-eclampsia [38], peripartum 
cardiomyopathy [39], and impaired ischemic limb vascularization [35].  
 
Up-regulation of Glutaredoxin inhibits neovascularization 
Adenoviral overexpression of Glrx in human aortic endothelial cells inhibited 
VEGF- and nitric oxide (NO)-induced network formation in vitro [40]. We 
investigated this finding in vivo using a mouse which overexpressed Glrx driven 
by the β-actin promoter. Up-regulation of Glrx resulted in diminished ischemic 
limb revascularization in a murine model of hind limb ischemia (HLI) [41]. 
Furthermore, both treadmill exercise function and capillary density in the 
gastrocnemius muscle post-HLI were significantly lower than observed in the 
wild-type littermate controls. EC function was measured in microvascular 
endothelial cells selectively (CD31+) isolated from Glrx TG mice [41]. Similar to 
previous observations in adenoviral Glrx overexpression HAECs, ECs isolated 
from GlrxTG mice had lower capability of VEGF-induced network formation,  
migration, and proliferation [41]. 
 
Glutaredoxin up-regulates Wnt5a-sFlt-1 in endothelial cells 
Interestingly, we found Wnt5a expression to be significantly higher in ischemic 
muscle and ECs from Glrx TG compared to WT control [41]. Likewise, sFlt-1 levels 
in plasma from Glrx TG mice after HLI and in the media of Glrx TG ECs were 
elevated. We revealed that Wnt5a-induced sFlt-1 was also evident in ECs, as 
recombinant Wnt5a treatment on human microvascular ECs induced sFlt-1, 
inhibiting network formation [41]. A pharmacological mimetic, Box 5, which 
competitively inhibits Wnt5a, prevented adenoviral Glrx-dependent increase of 
sFlt-1 suggesting Wnt5a regulated sFlt-1 in Glrx TG ECs. 
Furthermore, knockdown of sFlt-1 restored VEGF-induced migration and network 
formation in ECs overexpressing Glrx, confirming that enhanced sFlt-1 levels 
were contributing to Glrx-induced anti-angiogenic effects of EC, and Wnt5a was 
regulating sFlt-1 expression [41]. 
 
Increase in Wnt5a-sFlt-1 expression is p65-dependent 
Glrx enhancement of NF-κB activity has been well described[42]. Of importance, 
Wnt5a promoter B has a NF-κB binding site [43], conversely Wnt5a is able to 
enhance NF-κB activity suggesting the presence of a positive-feedback loop [44]. 
In hepatocytes, celecoxib (non-steroidal anti-inflammatory drug) suppressed 
Wnt5a expression by lowering NF-κB activity [45]. As predicted Glrx TG ECs 
indeed had the greater potential to enhance NF-κB activity in a luciferase 
reporter assay[41]. The biotin switch assay as mentioned previously was used to 
detect glutationylated proteins. Ischemia-induced p65–S-glutathionylation in the 
muscle[41], but the ischemic muscle from Glrx TG mice had significantly less p65-
S-glutationylation. In human ECs overexpressing Glrx S-glutathionylation of p65 
was completely abolished compared with ECs treated with the control 
adenovirus, AdLacZ. Exposing the ECs to hypoxic conditions could not induce 
p65-S-glutationylation in adGlrx overexpressing cells[41]. Interestingly, inhibition of 
NF-κB can increase tumor vascularization [46], which would be consistent with the 
current hypothesis that Glrx-mediated activation of NF-κB results in diminished 
angiogenesis via upregulation of Wnt5a and sFlt-1 (Figure 3). 
 
 
Summary 
 
Enhanced expression of Glrx has been reported in various pathologies that are 
associated with oxidative stress, including coronary artery disease and 
atherosclerotisis [47], allergic airway disease [28], and diabetic retinopathy [48]. 
Ischemic limb neovascularization was inhibited in the mice overexpressing Glrx 
in association with sFlt-1 induction. Diabetic patients have higher plasma Glrx 
levels [30] and a high prevalence for peripheral artery disease. In agreement, the 
impaired ischemic limb vascularization correlated with a disproportionate 
increase in sFlt-1 levels in a diabetic animal model [36]. It suggests that during 
ischemia S-glutathionylation is required to conduct angiogenic signaling, and that 
enhanced Glrx may contribute to the pathology of impairmed neo-vascularization. 
.  This pathway described for endothelial cells may also occur in other cell types, 
as Glrx is ubiquitously expressed. Cellular reduction systems are normally 
regarded to be cytoprotective. Our work, however, suggests that enhancing the 
Glrx-dependent anti-oxidant system does not promote beneficial ischemic limb 
neovascularization. 
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Figure 1:  Reactive protein thiolates undergo reversible or irreversible oxidation. Reactive 
oxygen species/ reactive nitrogen species (ROS/RNS) generate reversible intermediates 
including S-nitrosothiol (R-SNO) and sulfenic acid (R-SOH), which may become S-
glutathionylated protein (R-SSG). R-SOH can be further oxidized to generate irreversible 
modifications such as sulfonic acid (R-SO3H). ROS, reactive oxygen species; RNS, reactive 
nitrogen species; Glrx, Glutaredoxin; GSH, glutathione; Trx, thioredoxin. 
  
 
 
Figure 2:  Glutaredoxin system. R-SSG, S-glutathionylated protein; GR, glutathione reductase; 
Glrx, glutaredoxin-1, catalyze removal of GSH adducts in the presence of GSH and NADPH.  
 
 
  
Figure 3:  Enhanced endothelial Glrx increases NF-κB-dependent Wnt5a, upregulating the 
anti-angiogenic receptor sFlt-1.  Glrx, Glutaredoxin; VEGF, vascular endothelial growth factor; 
sFlt-1, soluble fms-like tyrosine kinase-1 (VEGFR1); Wnt5a, wningless-type MMTC integration 
site family, member 5A; ROR2, receptor tyrosine kinase-like orphan receptor 2;  –SSG, S-
glutathionylation. 
 
 
 
 
 
